Wednesday, July 8, 2026
🇺🇸 FDA

pharma · No medical condition. · Breast cancer

George Institute for

The George Institute

George Institute for trial registry — 406 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

George Institute for clinical trials

Registry index of 406 ClinicalTrials.gov studies linked to George Institute for programs — each row shows trial ID, program name, phase, status, and indication.

George Institute for trial registry — 406 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for George Institute for.

  1. HIPER-RESET — Phase 2

    Clinical update

  2. CTO # 2095 — Phase 3

    Clinical update

  3. CSET n° 2020/3210 — Phase 2

    Clinical update

  4. CSET 2023/3603 — Phase 3

    Clinical update

  5. CSET 2021/3373 — Phase 3

    Clinical update

  6. CL1-95029-002 — Phase 2

    Clinical update

  7. TESTOGEL for low ovarian reserve according t… — Approved

    Clinical update

  8. lurbinectedin for Advanced/Recurrent Endometrial… — Phase 2

    Clinical update

Trial registry

406 studies
  4. 2023-503218-56-00

    2022/3418 INDIGO

    Phase 2 active other

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    CTIS ↗
  5. 2023-503316-33-00

    2023/3720 UMBRELLA

    Phase 3 active small_molecule

    patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment

    CTIS ↗
  9. 2023-503606-36-00

    CSET 2022-3571

    Phase 2 active other

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    CTIS ↗
  10. 2023-503886-44-00

    CSET 2023/3603

    Phase 3 active small_molecule

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    CTIS ↗
  22. 2023-505380-36-00

    CSET 2021/3373

    Phase 3 active small_molecule

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    CTIS ↗
  23. 2023-505380-36-01

    CSET 2021/3373

    Phase 3 active small_molecule

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    CTIS ↗
  24. 2023-505431-12-00

    IC 2022-10

    Phase 1 active other

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    CTIS ↗
  29. 2023-505923-30-00

    CSET N° 2020/3188

    Phase 2 active other

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    CTIS ↗
  30. 2023-505924-71-00

    CSET 2020/3187

    Phase 2 active other

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    CTIS ↗
  31. 2023-505925-15-00

    2023/3668

    Phase 2 active other

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    CTIS ↗
  58. 2023-508507-20-00

    CL3-95031-007

    Phase 3 active small_molecule

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    CTIS ↗
  64. 2023-508730-34-00

    SPLFIO-174

    Phase 2 active small_molecule

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    CTIS ↗
  73. 2023-509494-23-00

    IB 2021-03

    Phase 2 active small_molecule

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    CTIS ↗
  77. 2023-509498-21-00

    IB 2021-01

    Phase 2 active small_molecule

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    CTIS ↗
  99. 2024-511265-11-01

    ICI22/00054

    Approved active small_molecule

    patients who are requested a colonoscopy for any indication and are under antiplatelet treatment (except ASA) or anticoagulant treatment

    CTIS ↗
  107. 2024-511477-29-00

    IRSSP-001

    Phase 2 active small_molecule

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    CTIS ↗
  123. 2024-512483-59-00

    TRACK_001

    Phase 3 active small_molecule

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    CTIS ↗
  132. 2024-512934-14-00

    RAMIRIS

    Phase 3 active small_molecule

    advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

    CTIS ↗
  135. 2024-512980-29-00

    PRESTO

    Phase 2 active small_molecule

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    CTIS ↗
  152. 2024-513947-94-00

    ABP-2019

    Phase 2 active small_molecule

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    CTIS ↗
  167. 2024-514356-33-00

    S227928

    Phase 2 active small_molecule

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    CTIS ↗
  180. 2024-514833-39-00

    SUITH

    Phase 1 active other

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    CTIS ↗
  207. 2024-515600-39-00

    RC-P0055

    Approved active small_molecule

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    CTIS ↗
  218. 2024-515968-32-00

    IVERMECTIN

    Phase 2 active small_molecule

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    CTIS ↗
  220. 2024-516026-56-00

    INSIGHT

    Phase 1 active other

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    CTIS ↗
  233. 2024-516660-28-00

    VHIO24001

    Phase 1 active other

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    CTIS ↗
  234. 2024-516660-28-01

    VHIO24001

    Phase 1 active other

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    CTIS ↗
  255. 2024-517391-38-00

    SIMA SPK 01

    Approved active small_molecule

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    CTIS ↗
  291. 2024-519350-37-00

    IFG-05-2019

    Phase 2 active small_molecule

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    CTIS ↗
  308. 2024-519788-16-00

    Valemetostat Tosylate, Valemetostat Tosylate

    Phase 2 active small_molecule

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    CTIS ↗
  313. 2024-519895-23-00

    Grafalon 20 mg/ml concentrato per soluzione per infusione

    Phase 3 active small_molecule

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    CTIS ↗
  329. 2024-520140-42-00

    2024/4031

    Phase 3 active small_molecule

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    CTIS ↗
  379. 2025-523139-21-00

    2G-MSC-GVHD

    Phase 2 active small_molecule

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    CTIS ↗
  380. 2025-523264-21-00

    C24-50

    Phase 3 active small_molecule

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.